Cargando…

Imprinted hybrid immunity against XBB reinfection

Detalles Bibliográficos
Autores principales:	Boyton, Rosemary J, Altmann, Daniel M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2023
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010702/ https://www.ncbi.nlm.nih.gov/pubmed/36924785 http://dx.doi.org/10.1016/S1473-3099(23)00138-X

Ejemplares similares

SARS-Cov-2 immune waning and reinfection in care-home settings
por: Altmann, Daniel M, et al.
Publicado: (2021)

Risk of SARS-CoV-2 reinfection after natural infection
por: Boyton, Rosemary J, et al.
Publicado: (2021)

Redirected vaccine imprinting by co-administration of COVID-19 and influenza vaccines
por: Boyton, Rosemary J., et al.
Publicado: (2023)

Waning immunity to SARS-CoV-2: implications for vaccine booster strategies
por: Altmann, Daniel M, et al.
Publicado: (2021)

Vaccine efficacy and immune interference: co-administering COVID-19 and influenza vaccines
por: Altmann, Daniel M, et al.
Publicado: (2022)

What policy makers need to know about COVID-19 protective immunity
por: Altmann, Daniel M, et al.
Publicado: (2020)

XBB.1.5 emerges in the Americas: what it means to the region
por: Hotez, Peter
Publicado: (2023)

What reinfections mean for COVID-19
por: Iwasaki, Akiko
Publicado: (2021)

Immune Imprinting and Protection against Repeat Reinfection with SARS-CoV-2
por: Chemaitelly, Hiam, et al.
Publicado: (2022)

COVID-19 infection, reinfection, and the transition to endemicity
por: Cohen, Cheryl, et al.
Publicado: (2023)

Two individuals with potential monkeypox virus reinfection
por: Raccagni, Angelo Roberto, et al.
Publicado: (2023)

Importance of understanding the reinfection risk of COVID-19 in children
por: Crawford, Nigel W
Publicado: (2022)

SARS-CoV-2 reinfection in a closed setting: lessons for the community
por: Velasco, María, et al.
Publicado: (2021)

The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2
por: Li, Jing-Xin, et al.
Publicado: (2022)

SARS-CoV-2 in Malaysia: A surge of reinfection during the predominantly Omicron period
por: Yang, Su Lan, et al.
Publicado: (2022)

Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
por: Shenoy, Padmanabha, et al.
Publicado: (2022)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?
por: Boyton, Rosemary J., et al.
Publicado: (2021)

Immune evasion and membrane fusion of SARS-CoV-2 XBB subvariants EG.5.1 and XBB.2.3
por: Faraone, Julia N., et al.
Publicado: (2023)

Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study
por: Tan, Celine Y, et al.
Publicado: (2023)

Hybrid immunity and strategies for COVID-19 vaccination
por: Hui, David S
Publicado: (2023)

SARS-CoV-2: from herd immunity to hybrid immunity
por: Goldblatt, David
Publicado: (2022)

In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1
por: Pochtovyi, Andrei A., et al.
Publicado: (2023)

XBB.1.5 spike protein COVID-19 vaccine induces broadly neutralizing and cellular immune responses against EG.5.1 and emerging XBB variants
por: Patel, Nita, et al.
Publicado: (2023)

Waning Immunity Against XBB.1.5 Following Bivalent mRNA Boosters
por: Lasrado, Ninaad, et al.
Publicado: (2023)

Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination
por: Irving, Stephanie A, et al.
Publicado: (2023)

Dawn of the hybrid immunity era in long-term care facilities
por: Poukka, Eero, et al.
Publicado: (2022)

Coding-Complete Genome Sequences of 40 SARS-CoV-2 Omicron XBB, XBB.1, and XBB.2 Sublineage Strains in Bangladesh
por: Habib, Mohammad Tanbir, et al.
Publicado: (2023)

BA.5 bivalent booster vaccination enhances neutralization of XBB.1.5, XBB.1.16 and XBB.1.9 variants in patients with lung cancer
por: Valanparambil, Rajesh M., et al.
Publicado: (2023)

SARS-CoV-2 variants: Subversion of antibody response and predicted impact on T cell recognition
por: Altmann, Daniel M., et al.
Publicado: (2021)

Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
por: McDonald, Ian, et al.
Publicado: (2021)

Coding-complete genomes of XBB.1.16, XBB.2.3, FL.4 (alias of XBB.1.9.1.4), and XBB.3 of SARS-CoV-2 Omicron isolated from Bangladesh
por: Rahman, Saikt, et al.
Publicado: (2023)

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?
por: Suryawanshi, Rahul, et al.
Publicado: (2022)

Population immunity and vaccine protection against infection
por: Leshem, Eyal, et al.
Publicado: (2021)

A recombinant spike‐XBB.1.5 protein vaccine induces broad‐spectrum immune responses against XBB.1.5‐included Omicron variants of SARS‐CoV‐2
por: He, Cai, et al.
Publicado: (2023)

BCG-induced trained immunity: can it offer protection against COVID-19?
por: O’Neill, Luke A. J., et al.
Publicado: (2020)

Humoral immune evasion of the omicron subvariants BQ.1.1 and XBB
por: Uraki, Ryuta, et al.
Publicado: (2023)

Antibiotic therapy and outcome from immune-checkpoint inhibitors
por: Pinato, David J., et al.
Publicado: (2019)

Emergence and geographic dominance of Omicron subvariants XBB/XBB.1.5 and BF.7 – the public health challenges
por: Velavan, Thirumalaisamy P., et al.
Publicado: (2023)

Efficacy of Antiviral Agents against Omicron Subvariants BQ.1.1 and XBB
por: Imai, Masaki, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tq4bulkp97vvm72ag0rm1g79pu